Understanding why placebos can have therapeutic benefit

Regular readers will be familiar with the fact that new drugs for prostate cancer are often tested against a “placebo.” They may also have heard the term “the placebo effect,” which generally implies that some interventions with no known (or theoretically possible) therapeutic benefit can be demonstrated to have a very real therapeutic effect. … READ MORE …

Abiraterone acetate in chemotherapy-naive mCRPC — Phase III trial outcome

This morning, at the ASCO annual meeting, Dr. Charles Ryan will present the full interim results of COU-AA-302, the randomized, Phase III study of abiraterone acetate in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 866 other followers